The world-class, low-cost gene editing solution named "BIRSA 101", in honour of Bhagwan Birsa Munda, remembered as a great ...

The FDA has granted approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, ...

Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...

The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).

Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...

New research shows a therapy that’s been used for cancer patients may help people with lupus go into remission.

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with ...

The sandwich therapy showed a 2-year overall survival rate of 97% and a leukemia-free survival rate of 72% in Ph-negative ...

DENVER -- Patients who discontinued treatment for advanced kidney cancer because of immune-related adverse events (irAEs) had ...

Tumor infiltrating lymphocyte (TIL) therapy uses immune cells harvested directly from a patient’s tumor.

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...